- Home
- VIVK vs BLRX Comparison
VIVK vs BLRX Comparison
Compare VIVK & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VIVK | BLRX |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 17.1M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | VIVK | BLRX |
|---|---|---|
| Price | $0.06 | $3.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 25.6M | 28.9K |
| Earning Date | 11-19-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,113,426.00 | $12,735,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 101.82 | N/A |
| 52 Week Low | $0.06 | $2.30 |
| 52 Week High | $1.49 | $14.70 |
Technical Indicators
Market Signals| Indicator | VIVK | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 27.38 | 37.42 |
| Support Level | $0.06 | $3.14 |
| Resistance Level | $0.09 | $3.36 |
| Average True Range (ATR) | 0.02 | 0.20 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 10.37 | 0.00 |
Price Performance
Historical ComparisonAbout VIVK Vivakor Inc.
Vivakor Inc is a socially responsible operator, acquirer and developer of technologies and assets in the oil and gas industry, as well as related environmental solutions. It is focused on operating crude oil gathering, storage and transportation facilities, as well as contaminated soil remediation services. Company have two operating business segments: Transportation logistics services; Terminaling and storage facility product and services related to oil and gas production. Majority of revenue is from Terminaling and storage segment.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.